Medical Marijuana: Federal Law vs. State Law Conflicts

Federal law classifies marijuana as a Schedule I controlled substance under the Controlled Substances Act. More than 40 states have passed laws permitting medical use. That gap — one federal prohibition sitting atop a patchwork of state permissions — is where patients, employers, physicians, and landlords all have to make decisions without a clean answer. This page maps the legal fault lines, explains how enforcement actually operates, and identifies the specific situations where the conflict matters most.

Definition and scope

Under the Controlled Substances Act (21 U.S.C. § 812), marijuana is classified Schedule I — meaning the federal government holds that it has no accepted medical use and a high potential for abuse. That classification has not changed since 1970, despite petitions to the DEA dating back decades. The Drug Enforcement Administration's 2024 proposal to move marijuana to Schedule III had not been finalized as of publication, and even a rescheduling to Schedule III would not legalize state medical programs in the way patients might assume.

State medical marijuana programs, by contrast, operate through state police power — the authority states have always held over public health and medical practice. As of 2024, 38 states plus the District of Columbia had enacted some form of medical marijuana law (National Conference of State Legislatures, 2024). Those laws create licensing frameworks, define qualifying conditions, and establish dispensary oversight — but none of them override federal law for federal purposes.

The result is a doctrine called dual sovereignty: a person can be fully compliant with their state's medical program and simultaneously be in technical violation of federal law. Both things are true at once.

How it works

Federal enforcement of marijuana laws against individual state-compliant patients has been largely restrained by a series of Congressional funding riders. The Rohrabacher-Blumenauer amendment (also called the Joyce Amendment), attached to successive federal appropriations bills since 2014, prohibits the Department of Justice from using federal funds to interfere with state medical marijuana programs. The DOJ's 2013 Cole Memorandum — since rescinded in 2018 but partially reflected in practice — had similarly directed federal prosecutors to deprioritize enforcement against state-compliant medical activity.

What this means in practice:

1. State-level compliance does not equal federal immunity. It means enforcement is unlikely, not impossible.
2. Federal property is a hard boundary. Possession on federal lands, in federal buildings, or on tribal land governed by federal law is not protected by state medical authorization.
3. Federal employment is a separate universe. Federal employees and contractors remain subject to federal drug-free workplace policies regardless of state law, a dynamic explored in detail on the medical marijuana workplace rights page.
4. Banking and finance run through federal systems. Dispensaries in fully legal states still struggle with banking access because federally chartered institutions risk prosecution under the Bank Secrecy Act.
5. Interstate transport is federal jurisdiction. Carrying medical marijuana across state lines — even between two states that both allow it — constitutes federal drug trafficking. The traveling across state lines page covers this specifically.

Common scenarios

The conflict surfaces most sharply in four real-world contexts.

Employment. A state medical card does not prevent termination or denial of employment in most private-sector contexts. Some states — including New Jersey, New York, and Connecticut — have enacted worker protections that prohibit adverse employment action based solely on off-duty medical marijuana use. Most states have not. Federal contractors and safety-sensitive positions governed by the Department of Transportation's drug testing rules have no protection at any level.

Housing. Federally subsidized housing — including Section 8 voucher housing and public housing authorities — operates under HUD guidelines that prohibit marijuana regardless of state law. The medical marijuana patient rights page addresses the limits of state-level protections in federal housing contexts.

Firearms. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) Form 4473 — required for all licensed dealer firearm sales — asks whether the buyer is an "unlawful user of or addicted to" a controlled substance. The ATF clarified in 2011 that marijuana users, including state-authorized medical patients, are prohibited from purchasing or possessing firearms under 18 U.S.C. § 922(g)(3). This applies in all 50 states.

Professional licensing. Healthcare providers, attorneys, and other licensed professionals in federally regulated contexts face separate layers of risk. A physician's DEA registrant number — required to prescribe controlled substances — is a federal authorization subject to federal standards.

Decision boundaries

The clearest distinction to hold is between state enforcement risk and federal enforcement risk. For most patients in compliant states, state enforcement risk is near zero — possession within program limits is expressly permitted. Federal enforcement risk is low but structurally present and dramatically higher in specific categories.

The categories where federal law dominates regardless of state permission:

The categories where state law provides meaningful real-world protection:

The regulatory context page provides a broader framework for how federal and state agencies interact across the medical marijuana landscape. For patients navigating insurance coverage or cost questions, the federal classification is the direct reason most private insurers and Medicare decline to cover cannabis — it remains a Schedule I substance in their regulatory universe, whatever a patient's home state has decided.